Skip to main content
. 2022 Aug 23;12:13717. doi: 10.1038/s41598-022-18266-w

Figure 4.

Figure 4

Targeted pharmacological dose–response activities of pentadecanoylcarnitine at ten concentrations (ranging from 0.1 to 20 µM), compared to internal positive controls. Detected pentadecanoylcarnitine activities included (a) cannabinoid receptor 1 agonist, (b) cannabinoid receptor 2 agonist, (c) histamine receptor 1 antagonist, (d) histamine receptor 2 antagonist, (e) 5-HT1A agonist, (f) 5-HT1B agonist.